Mobius FX, an add-on software module from Mobius Medical Systems™ for intensity-modulated radiation therapy (IMRT) quality assurance (QA), uses linac treatment logs to efficiently calculate and verify the 3D dose delivered to patients. An advantage of the Mobius FX module is that it does not require device positioning. In this study, we compared the Mobius FX with another QA option, ArcCheck, as well as with the treatment planning system (TPS) using 30 volumetricmodulated arc therapy (VMAT) plans planned and delivered on a Varian TrueBeam linac. The plans, which involved 6 and 10 MV and consisted of 2 to 3 arcs per plan, were selected to provide a clinically relevant sample. The average gamma value for all plans between Mobius FX and the TPS was 99.96% for the criterion of 3%-3 mm and 98.80% for the criterion of 2%-2 mm. Very similar results were found when comparing Mobius FX and the TPS dose calculations with those acquired by traditional methods (i.e., ArcCheck). As the gamma criterion of the analysis was narrowed, discrepancies between Mobius FX and traditional methods appeared. Profile analysis showed the production of comparable results when using the Mobius FX method or traditional QA methods. In conclusion, the Mobius FX method for pretreatment of patient-specific QA is capable of producing results similar to those obtained by traditional methods. W ith the introduction of intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) techniques, the complexity of the treatment plan in radiation oncology has increased along with the need for patient-specifi c pretreatment quality assurance (QA) measurements. Th e need for fast and reliable methods has created a wide variety of available solutions for IMRT QA, including ion chamber, diode array, electronic portal imaging device (EPID), fi lm, and radio-chromic fi lm measurements, which have been extensively studied and are widely accepted (1-15). Th e Mobius FX solution (Mobius Medical Systems, Houston, TX) for IMRT QA uses linac treatment logs to calculate and verify the 3D dose delivered. Th is approach is attractive since it does not require ion chamber, diode array, EPID, fi lm, or any external measurements and thus should be faster since no device needs to be positioned. In this study, we compared Mobius FX with ArcCheck (Sun Nuclear Corporation, Melbourne, FL), the standard QA tool used for IMRT that measures the actual dose or fl uence by means of a physical method. ArcCheck is a 4D measurement array that consists of 1386 SunPoint ® diode detectors (0.019 mm 3 ) arranged on a helical detector grid. Th is arrangement is specially designed for rotational deliveries. ArcCheck has proven to be a very reliable method for IMRT and VMAT patient-specifi c pretreatment QA (5, 6).
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METHODS
In this study, 30 VMAT plans were planned and delivered using a Varian TrueBeam linac (Varian Medical Systems, Palo Alto, CA). Th e plans were randomly selected and included diff erent treatment sites: lung, pelvis, brain, and head and neck. Th e plans included in the research were planned with 6 and 10 MV and consisted of 2 to 3 arcs per plan.
All VMAT plans were delivered and measured at the same time with ArcCheck ( Figure 1 ) and Mobius to ensure consistency in the data. Th e linac log fi les were acquired simultaneously, taking advantage of the Mobius FX method allowing both measurements to be made at the same time. Th e ArcCheck was calibrated at the beginning of the measurements to ensure dose calibration uniformity using an open fi eld and a known number of monitor units for a known dose. Th e Eclipse dose calculations were exported to Mobius before the start of the measurements so that Mobius FX could record and analyze the delivery occurring during the ArcCheck measurements.
Mobius FX uses the Mobius 3D dose calculation algorithm based on log fi les recorded from the linac during the IMRT QA, and it goes one step further by calculating the dose delivered to the patient for each fraction (Figure 2a ). In addition, it provides a detailed report that includes isodose, gamma analysis, dose volume histogram (Figure 2b) , and root mean square (RMS) analysis for each fraction of the patient treatment. Mobius 3D uses a collapse cone algorithm that has proven to be a highly accurate dose calculation engine (16, 17) .
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To preserve data uniformity, the gamma analyses and profi le analyses were performed using SNC PA software version 6.4.1 from Sun Nuclear Corporation. Dose calculations by Mobius FX based on the log fi les from the VMAT delivery were exported in a Digital Imaging and Communications in Medicine (DICOM) format and imported into the SNC PA software for comparison with ArcCheck measurements and the Eclipse treatment planning system (TPS) from Varian dose calculations. Gamma analyses for VMAT plans were conducted with a dose diff erence and distance-to-agreement criterion of 3%-3 mm and 2%-2 mm, respectively. All gamma analyses used the same algorithm for consistency. Dose profi le comparisons were conducted at the same time the gamma analyses were being conducted in the SNC PA software. Th e dose profi les were evaluated in the horizontal, vertical, and diagonal directions of the dose plane.
RESULTS
Profi les and gamma analyses were compared on all VMAT QA plans. Th e average gamma values with criterion of 3%-3 mm and 2%-2 mm for the comparison for ArcCheck-Mobius FX, ArcCheck-TPS, and Mobius FX-TPS are presented in Table 1 . Figure 3 presents gamma analysis comparisons of 1) the ArcCheck-measured dose with the Mobius FX dose; 2) the ArcCheck-measured dose with the Eclipse TPS dose; and 3) the Mobius FX dose calculated based on the linac log fi les with the Eclipse TPS dose calculation. Similar results were found in the other cases analyzed.
DISCUSSION
In the gamma analyses, comparable values were observed with the TPS calculation for the 3%-3 mm and 2%-2 mm criterion among ArcCheck and Mobius FX. When comparing Mobius FX directly to ArcCheck at the 3%-3 mm criterion, small discrepancies were observed. When increasing the criterion to 2%-2 mm, larger discrepancies between the methods were observed. Th e diff erences were observed in diff erent regions when comparing Mobius FX and ArcCheck to TPS dose calculations. As a result of direct comparison between Mobius FX and ArcCheck, we can check the diff erences between both VMAT QA methods.
Our results showed a similar trend when comparing Mobius FX to the TPS dose calculations and those acquired by traditional methods. As the gamma criterion of the analysis was narrowed, discrepancies between Mobius FX and traditional methods appeared in the analyses due to the diff erent One of the main critiques from the community to move towards IMRT QA based on machine log fi les is the lack of physical measurement. Several solutions have been proposed, such as the use of ion chamber measurement during the delivery to ensure the output of the machine and the daily verifi cation of the output and MLC positioning through EPID, that could complement the use of machine log fi les.
Dose verifi cation based on the daily delivery of the treatment in radiation oncology has become a novel aspect of the daily checks in medical physics. Until recently, this information was not available to physicists through log fi les or other means. Th e information provided through new technologies can provide a way to evaluate day-to-day delivery and to approach IMRT QA in general. Monitoring of daily log fi les can provide a route to identify problems with treatment delivery and any deviation of MLC positioning so that issues can be detected and corrected before the machine mechanism can detect MLC failure by analyzing the RMS deviations from the planned and previous treatment deliveries.
